Optimizing drug delivery systems using systematic "design of experiments." Part I: Fundamental aspects

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 22, Issue 1, 2005, Pages 27-105

  Singh, Bhupinder ^a   Kumar, Rajiv ^a   Ahuja, Naveen ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Artificial neural networks; Computer software; Drug product development; Experimental design; Factor screening; Response surface methodology

Indexed keywords

ANALYTIC METHOD; ARTIFICIAL NEURAL NETWORK; COMPUTER AIDED DESIGN; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; EXPERIMENTAL DESIGN; EXPERIMENTATION; FACTOR SCREENING; INFORMATION PROCESSING; INFORMATION RETRIEVAL; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PLANNING; PROBLEM SOLVING; PROCESS OPTIMIZATION; PRODUCT ANALYTICAL INSTRUMENT; PRODUCT DEVELOPMENT; QUANTITATIVE ANALYSIS; RESPONSE SURFACE ANALYSIS; REVIEW; SCREENING; SYSTEMATIC DESIGN OF EXPERIMENTS; VALIDATION PROCESS; DRUG INCOMPATIBILITY; MATHEMATICAL COMPUTING; METHODOLOGY; PHARMACEUTICS; REPRODUCIBILITY; STATISTICAL MODEL; STATISTICS;

DRUG DELIVERY SYSTEMS; DRUG INCOMPATIBILITY; MODELS, STATISTICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 20044377802     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v22.i1.20     Document Type: Review

References (138)

1. Lee VHL. Advanced drug delivery reviews: cornerstone in the stimulation and dissemination of innovative drug delivery research. Adv Drug Deliv Rev 2004; 56:1-2.
2. Crommelin DJA, Storm G, Jiskoot W, Stenekes R, Mastrobattista E, Hennink WE. Nanotechnological approaches for the delivery of macromolecules. J Control Release 2003; 87:81-88.
3. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255:13-32.
4. Lewis GA. Optimization methods. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. 2nd ed. New York: Marcel Dekker, 2002.
5. Kannan V, Kandarapu R, Garg S. Optimization techniques for the design and development of novel drug delivery systems, part I. Pharm Tech 2003; Feb:74-90.
6. Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical Experimental Design. 1st ed. New York: Marcel Dekker, 1999.
7. Montgomery DC. Design and Analysis of Experiments. 5th ed. New York: Wiley, 2001.
8. Araujo PW, Brereton RG. Experimental design II. Optimization. Trends in Anal Chem 1996; 15:63-70.
9. Tye H. Application of statistical "design of experiments" methods in drug discovery. Drug Discov Today 2004; 9:485-491.
10. Shekh E, Ghani M, Jones RE. Simplex search in optimization of capsule formulation. J Pharm Sci 1980; 69:1135-1142.
11. Fonner DE, Buck JR, Banker GS. Mathematical optimization techniques in drug product design and process analysis. J Pharm Sci 1970; 59:1587-1596.
12. Bolhuis GK, Duineveld CAA, de Boer JH, Coenegracht PMJ. Simultaneous optimization of multiple criteria in tablet formulation: Part I. Pharm Tech 1995; Jun: 42-50.
13. Huisman R, van Kamp HV, Weyland JW, Doornbos DA, Bolhuis GK, Lerk CE Development and optimization of pharmaceutical formulations using a simplex lattice design. PharmWeek Sci 1984; 6:185-194.
14. Trygg J, Wold S. Introduction to statistical experimental design - what it is? Why and where is it useful? Editorial page, 2002, www.acc.umu.se/~tnkjtg/ Chemometrics/ Editorial, accessed on 30th August, 2004.
15. Singh B, Gupta RK, Ahuja N. Computer-assisted optimization of pharmaceutical formulations. In: Jain NK, editor. Pharmaceutical Product Development. New Delhi: CBS Publishers, 2004; in press.
16. Schwartz JB, Connor RE. Optimization techniques in pharmaceutical formulation and processing. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. 3rd ed. New York: Marcel Dekker, 1996.
17. Banker GS, Anderson NR.Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Varghese Publishing House, 1987.
18. Singh B, Ahuja N. Development of controlled-release buccoadhesive hydrophilic matrices of diltiazem hydrochloride: optimization of bioadhesion, dissolution, and diffusion parameters. Drug Dev Ind Pharm 2002; 28:433-444.
19. Singh B, Ahuja N. Response surface optimization of drug delivery system. In: Jain NK, editor. Progress in Controlled and Novel Drug Delivery Systems. 1st ed. New Delhi: CBS Publishers, 2004.
20. Colbourn EA, Rowe RC. Neural computing boosts formulation productivity. Pharm Tech IT Innov 2003; (Suppl):22-25.
21. Podczeck F. The development and optimization of tablet formulations using mathematical methods. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. New York: Marcel Dekker, 1996.
22. Armstrong NA, James KC. Understanding Experimental Designs and Interpretation in Pharmaceutics. London: Ellis Horwood, 1990.
23. Doornbos DA. Optimization in pharmaceutical sciences. Pharm Week Sci 1981; 3:33-61.
24. Fisher RA. The Design of Experiments. 1st ed. Edinburgh: Oliver and Boyd, 1935.
25. Schwartz J, Flamholz J, Press R. Computer optimization of pharmaceutical formulations I: general procedure. J Pharm Sci 1973; 62:1165-1170.
26. Haaland PD. Experimental Design in Biotechnology. New York: Marcel Dekker, 1989.
27. Fisher RA. Statistical Methods for Research Workers. Edinburgh: Oliver and Boyd, 1925.
28. Doornbos DA, de Haan P. Optimization techniques in formulation and processing. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 1995.
29. Kettaneh-Wold N. Use of experimental design in the pharmaceutical industry. J Pharm Biomed Anal 1991; 9:605-610.
30. Porter SC, Verseput RP, Cunnigham CR. Process optimization using design of experiemnts. Pharm Tech 1997; October:1-7.
31. Anonymous. Nist/sematech e-handbook of statistical methods. www.itl.nist.gov/div898/handbook/, 2002.
32. Bolhuis GK, Duineveld CAA, de Boer JH, Coenegracht PMJ. Simultaneous optimization of multiple criteria in tablet formulation: Part II. Pharm Tech 1995; September: 42-51.
33. Bolton S. Optimization techniques. In: Pharmaceutical Statistics: Practical and Clinical Applications. 3rd ed. New York: Marcel Dekker, 1997.
34. Cochran WC, Cox GM. Experimental Design. 2nd ed. New York: Wiley, 1992.
35. Down GRB, Miller RA, Chopra SK, Millar JF. Use of a desk top computer in a search type optimization of tablet formulations. Drug Dev Ind Pharm 1980; 6:311-330.
36. Bohidar NR, Restaino FA, Schwartz JB. Selecting key parameters in pharmaceutical formulations factors by regression analysis. Drug Dev Ind Pharm 1979; 5:175-216.
37. Schwartz JB, Flamholz JR, Press RH. Computer optimization of pharmaceutical formulations II: Application in trouble shooting. J Pharm Sci 1973; 62:1518-1519.
38. Potter CD. Experiment design software: Better data, less work.The Scientist 1994; 8:18-20.
39. Stetsko G. Statistical experimental design and its application to pharmaceutical development problem. Drug Dev Ind Pharm 1986; 12:1109-1123.
40. Bolton S. Factorial designs. In: Pharmaceutical Statistics: Practical and Clinical Applications. 3rd ed. New York: Marcel Dekker, 1997.
41. Anderson M, Kraber S, Hansel H, Klick S, Beckenbach R, Cianca-Betancourt H. Design Expert® Software Version 6 User's Guide. MN: Statease Inc., 2002.
42. Box GEP, Connor LR, Cousins WR, Davies OL, Himsworth FR, Sillitto GP, editors. The Design and Analysis of Industrial Experiments. 2nd ed. London: Oliver and Boyd, 1960.
43. Taguchi G. System of Experimental Designs. New York: UNIPUB/Krauss International, 1987.
44. Stack CB. Confounding and interaction. In: Chow S-C, editor. Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker, 2003.
45. Myers RH, Montgomery DC. Response Surface Methodology: Process and Product Optimization using Designed Experiments. New York: Wiley, 1995.
46. Box GEP, Draper NR. Empirical Model-Building and Response Surfaces. 1st ed. New York: Wiley, 1987.
47. Das MN, Giri NC. Design and Analysis of Experiments. 2nd ed. New Delhi: Wiley Eastern Limited, New Age International Limited, 1994.
48. Singh B, Agarwal R. Design development and optimization of controlled release microcapsules of diltiazem hydrochloride. Indian J Pharm Sci 2002; 64:378-385.
49. Wehrlé P, Stamm A. Statistical tools for process control and quality improvement in the pharmaceutical industry. Drug Dev Ind Pharm 1994; 20:141-164.
50. Loukas YL. A 2 (k-p) fractional factorial design via fold over: application to optimization of novel multicomponent vesicular system. Analyst 1997; 122:1023-1027.
51. Korsemeyer RW, Gurny R, DoElker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15:25-35.
52. Singh B, Chakkal SK, Ahuja N. Computer-aided design, development and optimization of controlled release mucoadhesive formulations of atenolol. In: Proceedings of National Seminar on Pharmaceutics in the Light of Drug Delivery Challenges; Chandigarh, India, 2003.
53. Box GEP, Hunter WG, Hunter JS. Statistics for Experimenters. New York: Wiley, 1978.
54. Myers WR. Response surface methodology. In: Chow S-C, editor. Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker, 2003.
55. Kannan V, Kandarapu R, Garg S. Optimization techniques for the design and development of novel drug delivery systems, part II. Pharm Tech 2003; March: 102-118.
56. Murphy JR. Screening design. In: Chow S-C, editor. Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker, 2003.
57. Anonymous. JMP® Design of Experiments, Version 5 User's Guide. Cary: SAS International, 2002.
58. Abu-Izza K, Garcia-Contreras L, Lu DR. Preparation and evaluation of sustained release AZT loaded microspheres: optimization of the release characteristics using response surface methodology. J Pharm Sci 1996; 85:144-149.
59. Wehrlé P, Nobelis P, Cuiné A, Stamm A. Response surface methodology: an interesting statistical tool for process optimization and validation: example of wet granulation in a high shear mixer. Drug Dev Ind Pharm 1993; 19:1637-1653.
60. Li J. Factorial designs. In: Chow S-C, editor. Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker, 2003.
61. Acikgöz M, Kas H, Orman M, Hincal A. Chitosan microspheres of diclofenac sodium: I. Application of factorial design and evaluation of release kinetics. J Micoencapsul 1996; 13:141-160.
62. Korakianiti ES, Rekkas DM, Dallas PP, Choulis NH. Optimization of the pelletization process in a fluid-bed rotor granulator using experimental design. AAPS PharmSciTech 2000; 1:article 35: 1-5.
63. Loukas YL. Computer-based expert system designs and analyzes a 2(k-p) fractional factorial design for the formulation optimization of novel multicomponent liposomes. J Pharm Biomed Anal 1998; 17:133-140.
64. Eddington ND, Ashraf M, Augsburger LL, Leslie JL, Fossler MJ, Lesko LJ, Shah VP, Rekhi GS. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol 1998; 3:535-547.
65. Plackett RL, Burman JP. The design of optimum multifactorial experiments. Biometrica 1946; 33:305-325.
66. Loukas YL. A Plackett-Burman screening design directs the efficient formulation of multicomponent DRV liposomes. J Pharm Biomed Anal 2001; 26:255-263.
67. Pena Romero A, Costa JB, Castel-Marteaux I, Chulia D. Statistical optimization of a controlled release formulation obtained by a double compression process: application of an Hadamard matrix and a factorial design. Drug Dev Ind Pharm 1989; 15:2419-2440.
68. Ozil P, Rochat MH. Experimental design, an efficient tool for studying the stability of parenteral nutrition. Int J Pharm 1988; 42:11-14.
69. Li JZ, Rekhi GS, Augsburger LL, Shangraw RF. The role of intra- and extragranular microcrystalline cellulose in tablet dissolution. Pharm Dev Technol 1996; 1:343-355.
70. Box GEP, Wilson KB. On the experimental attainment of optimum conditions. J Royal Stat Soc Ser B 1951; 13:1-45.
71. Box GEP, Behnken DW. Some new three-level designs for the study of quantitative variables.Technometrics 1960; 2:455-475.
72. Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using Box-Behnken design and desirability function. Drug Dev Ind Pharm 1998; 24:145-155.
73. Westerhuis JA, Coenegracht PMJ. Multivariate modelling of the pharmaceutical two-step process of wet granulation and tabletting with multiblock partial least squares. J Chemometrics 1997; 11:372-392.
74. Bodea A, Leucuta SE. Optimization of hydrophilic matrix tablet using a D-optimal design. Int J Pharm 1997; 153:247-255.
75. Fassihi R, Fabian J, Sakr AM. Application of response surface methodology to design optimization in formulation of a typical controlled release system. Drugs made in Germany 1996; 39:122-126.
76. Lin AY, Muhammad NA, Pope D, Augsburger LL. A study of the effects of curing and storage conditions on controlled release diphenhydramine HCl pellets coated with Eudragit NE30D. Pharm Dev Technol 2003; 8:277-287.
77. Shah RD, Kabadi M, Pope DG, Augsburger LL. Physico-mechanical characterization of the extrusion-spheronization process. Part 2. Rheological determinants for successful extrusion and spheronization. Pharm Res 1995; 12:496-507.
78. Kramar A, Turk S, Vrecer F. Statistical optimization of diclofenac sustained release pellets coated with polymethacrylic films. Int J Pharm 2003; 256:43-52.
79. Podczeck F. The development and optimization of tablet formulations using mathematical methods. In: Alderborn G, Nystrom C, editors. Pharmaceutical Powder Compaction Technology. New York: Marcel Dekker, 1995.
80. Pinto JF, Podczeck F, Newton JM. Investigations of tablets prepared from pellets produced by extrusion and spheronisation. II. Modelling the properties of the tablets produced using regression analysis. Int J Pharm 1997; 152:7-16.
81. Chatchawalsaisin J, Podczeck F, Newton JM. The influence of chitosan and sodium alginate and formulation variables on the formation and drug release from pellets prepared by extrusion/spheronisation. Int J Pharm 2004; 275:41-60.
82. DoEhlert DH. Uniform shell designs. Appl Stat 1970; 19:231-239.
83. Vojnovic D, Moneghini M, Rubessa F. Experimental design for a granulation process with "a priori" criterias. Drug Dev Ind Pharm 1995; 21:823-831.
84. Snee RD. Design and analysis of mixture experiments. J Qual Technol 1971; 3:159-169.
85. Cornell JA. Experiments with Mixtures: Design, Models, and the Analysis of Mixture Data. 2nd ed. New York: Wiley, 1990.
86. Cornell JA. Experiments with mixtures: An update and bibliography. Technometrics 1979; 21:95-106.
87. van Kamp HV, Bolhuis GK, Lerk CF. Optimization of a formulation for direct compression using a simplex lattice design. PharmWeek Sci 1987; 9:265-273.
88. Scheffé H. Experiments with mixtures. J Royal Stat Soc Ser B 1958; 20:344-360.
89. Ferrari F, Bertoni M, Bonferoni CM, Rossi S, Caramella C. Dissolution enhancement of an insoluble drug by physical mixture with a superdisintegrant: optimization with a simplex lattice design. Pharm Dev Technol 1996; 1:159-164.
90. Hirata M, Takayama K, Nagai T. Formulation optimization of sustained release tablet of chlorpheniramine maleate by means of extreme vertices design and simultaneous optimization technique. Chem Pharm Bull 1992; 40:741-746.
91. Campisi B, Chicco D, Vojnovic D, Phan-Tan-Luu R. Experimental design for a pharmaceutical formulation: optimization and robustness. J Pharm Biomed Anal 1998; 18:57-65.
92. Taguchi G. Introduction to Quality Engineering. White Plains, New York: UNIPUB/Krauss International, 1986.
93. Wehrle P, Palmieri GF, Stamm A. The Taguchi's performance statistic to optimize theophylline beads production in a high-speed granulator. Drug Dev Ind Pharm 1994; 20:2823-2843.
94. Yang SC, Zhu JB. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev Ind Pharm 2002; 28:265 - 274.
95. Palmieri GF, Wehrle P. Evaluation of ethylcellulose coated pellets optimized using the approach of Taguchi. Drug Dev Ind Pharm 1997; 23:1069-1077.
96. Lewis GA, Chariot M. Non classical experimental designs in pharmaceutical formulations. Drug Dev Ind Pharm 1991; 17:1551-1570.
97. de Aguiar PF, Bourguignon B, Khots MS, Massart DL, Phan Tan Luu R. D-optimal designs. Chemom Intell Lab Syst 1995; 30:199-210.
98. Chariot M, Lewis GA, Mathieu D, Phan Tan Luu R, Stevens HNE. Experimental design for pharmaceutical process characterisation and optimization using an exchange algorithm. Drug Dev Ind Pharm 1988; 14:2535-2556.
99. n factorial designs.Technometrics 1967; 9:569-575.
100. Nielloud F, Mestres JP, Fortune R, Draussin S, Marti-Mestres G. Formulation of oil-in-water submicron emulsions in the dermatological field using experimental design. Polymer Int 2003; 52:610-613.
101. Khan MA, Karnachi AA, Singh SK, Sastry SV, Kislalioglu SM, Bolton S. Controlled release coprecipitates: formulation considerations. J Control Release 1995; 37:131-141.
102. Zhou F, Vervaet C, Massart DL, Massart B, Remon JP. Optimization of the processing of matrix pellets based on the combination of waxes and starch using experimental design. Drug Dev Ind Pharm 1998; 24:353-358.
103. Lindberg N-O, Lundstedt T. Application of multivariate analysis in pharmaceutical development. Drug Dev Ind Pharm 1995; 21:987-1007.
104. Bolton S. Linear regression and correlation. In: Pharmaceutical Statistics: Practical and Clinical Applications. 3rd ed. New York: Marcel Dekker, 1997.
105. Myers RH. Classical and Modern Regression with Applications. Boston: PWS-KENT Publishing, 1990.
106. Pattarino F, Marengo E, Gasco MR, Carpignano R. Experimental design and partial least squares in the study of complex mixtures: microemulsions as drug carriers. Int J Pharm 1993; 91:157-165.
107. Bohidar NR, Restaino FA, Schwartz JB. Selecting key parameters in pharmaceutical formulations by principal component analysis. J Pharm Sci 1975; 64:966-969.
108. Benkerrour L, Duchene D, Puisieux F, Maccario J. Granule and tablet formulae study by principal component analysis. Int J Pharm 1984; 19:27-34.
109. Liu A, Schisterman EF. Principal component analysis. In: Chow S-C, editor. Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker, 2004.
110. Bolton S. Analysis of variance. In: Pharmaceutical Statistics: Practical and Clinical Applications. 3rd ed. New York: Marcel Dekker, 1997.
111. Bolton S. Statistical applications in the pharmaceutical sciences. In: Lachman L, Lieberman HA, Kanig JL, editors.The Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Varghese Publishing House, 1987.
112. Singh B, Mehta G, Kumar R, Bhatia A, Ahuja N, Katare OP. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr Drug Deliv 2005. [In press.]
113. Bolton S. Transformations and outliers. In: Pharmaceutical Statistics: Practical and Clinical Applications. 3rd ed. New York: Marcel Dekker, 1997.
114. Cook DR. Detection of influential observations in linear regression. Technometrics 1977; 19:15-18.
115. Box GEP, Cox DR. An analysis of transformations. J Royal Stat Soc Ser B 1964; 26:211-243.
116. Takayama K, Nagai T. Novel computer optimization methodology for pharmaceutical formulations investigated by using sustained release granules of indomethacin. Chem Pharm Bull 1989; 37:160-167.
117. Senderak E, Bonsignore H, Mungan D. Response surface method as an approach to optimization of an oral solution. Drug Dev Ind Pharm 1993; 19:405-424.
118. Law MFL, Deasy PB. Use of canonical and other analyses for the optimization of an extrusion-spheronization process for indomethacin. Int J Pharm 1997; 146:1-9.
119. Gonzalez AG. Optimization of pharmaceutical formulations based on surface-response experimental designs. Int J Pharm 1993; 97:149-159.
120. Shah S, Morris J, Sulaiman A, Farhadieh B, Truelove J. Development of misopristol 3 hour controlled release formulations using response surface methodology. Drug Dev Ind Pharm 1992; 18:1079-1098.
121. Bohidar NR, Bavitz JF, Shiromani PK. Formula optimization for a multiple potency system with uniform tablet weight. Drug Dev Ind Pharm 1986; 12:1503-1510.
122. Lin K, Peck GE. Development of agglomerated talc. Part 2. Optimization of the processing parameters for the preparation of granulated talc. Drug Dev Ind Pharm 1995; 21:159-173.
123. Westerhuis JA, de Haan P, Zwinkels J, Jansen WT, Coenegracht PMJ, Lerk CF. Optimization of the composition and production of mannitol/microcrystalline cellulose tablets. Int J Pharm 1996; 143:151-162.
124. Bouckaert S, Massart DL, Massart B, Remon JP. Optimization of a granulation procedure for a hydrophilic matrix tablet using experimental design. Drug Dev Ind Pharm 1996; 22:321-327.
125. Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Tech 1980; 12:214-219.
126. Takayama K, Imaizumi H, Nambu N, Nagai T Mathematical optimization of formulation of indomethacin/polyvinylpyrrolidone/methyl cellulose solid dispersions by the sequential unconstrained minimization technique. Chem Pharm Bull 1985; 33:292-300.
127. Fiacco AV, McCormik GP. Nonlinear Programming: Sequential Unconstrained Minimization Techniques. New York: Wiley, 1968.
128. Lipp R, Heimann G. Statistical approach to optimization of drying conditions for a transdermal delivery system. Drug Dev Ind Pharm 1996; 22:343-348.
129. Schwartz JB. Optimization techniques in product formulation. J Soc Cosmet Chem 1981; 32:287-301.
130. Takayama K, Fujikawa M, Obata Y, Morishita M. Neural network based optimization of drug formulations. Adv Drug Deliv Rev 2003; 55:1217-1231.
131. Takayama K, Takahara J, Fujikawa M, Ichikawa H, Nagai T. Formula optimization based on artificial neural networks in transdermal drug delivery. J Control Release 1999; 62:161-170.
132. Achanta AS, Kowalski JG, Rhodes CT. Artificial neural networks: implications for pharmaceutical sciences. Drug Dev Ind Pharm 1995; 21:119-155.
133. Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev 2003; 55:1201-1215.
134. Kuppuswamy R, Anderson SR, Hoag SW, Augsburger LL. Practical limitations of tableting indices. Pharm Dev Technol 2001; 6:505-520.
135. Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Application of artificial neural netrworks (ANN) in the development of solid dosage forms. Pharm Dev Technol 1997; 2:111-121.
136. Zupancic Božic D, Vrecer F, Kozjek F. Optimization of diclofenac sodium dissolution from sustained release formulations using an artificial neural network. Eur J Pharm Sci 1997; 5:163-169.
137. So S-S, Karplus MJ. Evolutionary optimization in quantitaive structure activity relationship: an application of genetic neural networks. J Med Chem 1996; 39:1521-1530.
138. Singh B. Computer-aided education in pharmaceutical sciences. Ind J Pharm Educ 1997; 31:93-102.